<!DOCTYPE html>


<style>
    body{
  background: #18181B;
}

.main{
  font-family: "Noto Sans", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Noto Color Emoji";
  color: #FDFDFD;
}

h1 {
  font-size: 2.5rem;
  color: white;
}

h3 {
  font-size: 1.5rem;
  background: #0c087c;
  padding: 10px;
  margin: 0px;
  border: 1px solid #6b7280;}

.extended-title{
  width:100%;
}

#gsk-overview{
  display:flex;
}

h4 {
  font-size: 1rem;
  background: #27272A;
  padding: 10px;
  margin: 0px;
  border-bottom: 1px solid #6b7280;
}

h2 {
  font-size: 1.5rem;
  margin-top: 3px;
  color:#000000;
}

.header{
  display: flex;
  justify-content: center;
  align-items: center;
}
.header > * {
  margin-inline: 20px;
}

.flex-row {
  display: flex;
  flex-direction: row;
  padding:10px;
  border: 1px solid #27272A;
}

.flex-row>div {
  flex: auto;
  box-sizing: border-box;
  display: flex;
  flex-direction: column;
  justify-content: center;
  align-items: center;
}

progress[value] {
  --background: #6D6D6D;
  -webkit-appearance: none;
  -moz-appearance: none;
  appearance: none;
  border: none;
  height: 4px;
  margin: 0 10px;
  border-radius: 10em;
  background: var(--background);
}

progress[value]::-webkit-progress-bar {
  border-radius: 10em;
  background: var(--background);
}

progress[value]::-webkit-progress-value {
  border-radius: 10em;
  background: var(--color);
}

progress[value]::-moz-progress-bar {
  border-radius: 10em;
  background: var(--color);
}

label {
  font-size: 20px;
  font-weight: bold;
  display: block;
  margin: 20px 0;
}

.tab {
  overflow: hidden;
  border: 1px solid #27272A;
  background-color: #27272A;
}

.tab button {
  background-color: inherit;
  float: left;
  border: none;
  outline: none;
  cursor: pointer;
  padding: 14px 16px;
  transition: 0.3s;
  color: #ffffff;
  font-size:1.2rem;
}

.tab div {
  background-color: inherit;
  float: left;
  border: none;
  outline: none;
  cursor: pointer;
  padding: 14px 16px;
  transition: 0.3s;
  color: #ffffff;
  font-size: 1.2rem;
}

.tab button:hover {
  background-color: #18181B;
}

.tab-title{
  font-size: 1.5rem;
  font-weight: bold;
  margin-bottom:-5px;
}

.tab button.active {
  background-color: #18181B;
  border-top: 1px solid #6b7280;
  border-bottom: 1px solid #18181B;
  border-left: 1px solid #6b7280;
  border-right: 1px solid #6b7280;
}

.tabcontent {
  display: none;
  padding: 6px 12px;
  background: #18181B;
  border: 1px solid #27272A;
  border-top: 1px solid #6b7280;
  margin-top: -2px;
}

#gsk-advice {
  display: flex;
  justify-content: center;
}

#gsk-metrics{
  width:100%;
}

#recommendation {
  margin-top: 20px;
  padding: 20px;
  border-radius: 10px;
  background-color: #e1ce86;
  color: #27272A;
  width:95%;
  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;
  font-size: 12pt;
}

.separator {
  margin: 20px 0;
}

.separator-border {
  margin: 20px 0;
  border-bottom: 1px solid #6b7280;
}

#gsk-rag{
  margin: 32px 28px;
  padding: 12px 24px;
  background-color: #111516;
}

.section-container {
  margin-bottom: 32px;
}

  .components-container {
    display: flex;
    flex-flow: row wrap;
    align-items: flex-start;
    gap: 0 32px;
  }

    .component-card {
      background-color: #14191B;
      border-radius: 16px;
      padding: 28px 32px 32px 32px;
      display: flex;
      flex-flow: column;
      align-items: center;
      margin-top: 32px;
      flex-grow: 1;
    }

    .component-title {
      font-size: 12px;
      font-weight: 500;
      color: #B1B1B1;
      padding-bottom: 8px;
    }

    .component-value {
      font-size: 32px;
      font-weight: 500;
      padding-bottom: 12px;
    }
      
      .text-green {
        color: #04B543;
      }
      
      .text-orange {
        color: #E76E0F;
      }
      
      .text-red {
        color: #EA3829;
      }

      .tooltip {
        position: relative;
        display: inline-block;
      }

      .tooltip .tooltiptext {
        visibility: hidden;
        width: 120px;
        background-color: #464646;
        color: #E6E6E6;
        text-align: center;
        border-radius: 6px;
        position: absolute;
        z-index: 1;
        top: 150%;
        left: 50%;
        margin-left: -60px;
        font-size: 12px;
        padding: 12px;
      }
      
      .tooltip .tooltiptext::after {
        content: "";
        position: absolute;
        bottom: 100%;
        left: 50%;
        margin-left: -5px;
        border-width: 5px;
        border-style: solid;
        border-color: transparent transparent black transparent;
      }
      
      .tooltip:hover .tooltiptext {
        visibility: visible;
      }

    .overall-card {
      background-color: #026836;
      border-radius: 16px;
      padding: 28px 32px 32px 32px;
      display: flex;
      flex-flow: column;
      align-items: center;
      justify-content: center;
      margin-top: 32px;
      flex-grow: 1;
    }
  
    .overall-title {
      font-size: 12px;
      font-weight: 500;
      color: #E6E6E6;
      padding: 14px 0 8px 0;
      text-transform: uppercase;
     }
  
    .overall-value {
      font-size: 32px;
      font-weight: 500;
      padding-bottom: 12px;
      color: #E6E6E6;
    }

.section-title {
  font-size: 12px;
  color: #B1B1B1;
  margin-bottom: 20px;
  text-align: left;
  width: 100%;
}

.section-content {
  color: #E6E6E6;
  font-size: 20px;
  line-height: 1.5;
}

.section-card {
  background-color: #14191B;
  border-radius: 16px;
  padding: 28px 32px 32px 32px;
  display: flex;
  flex-flow: column;
  align-items: center;
}

.correctness-indicator{
  padding: 20px;
  border-radius: 50px;
  font-size: 16pt;
  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;
  text-align: center;
}

.metric-title{
  margin: -2px;
  border-bottom: none;
}

.hist-row {
  display: flex;
  flex-direction: row;
  padding: 10px;
  justify-content: space-around;
  width: 85%;
}

.hist-row>div {
  flex: auto;
  box-sizing: border-box;
  display: flex;
  flex-direction: column;
  justify-content: center;
  align-items: center;
  padding-left: 1%;
  padding-right: 1%;
}

.tab-row{
  display: flex;
  flex-direction: column;
  align-items: center;
}

#component-table{
  width:50%;
  margin-top: 10px;
}

.green{
  background-color: #0a980a;
}

.orange {
  background-color: #e5b62a;
}

.red {
  background-color: #ba0e0e;
}

.progress-green {
  --color: #04B543;
}

.progress-orange {
  --color: #E76E0F;
}

.progress-red {
  --color: #EA3829;
}

.corr-plot{
  flex: 1;
  padding-left: 2%;
}

.tooltip-text {
  position: absolute;
  display: none;
  visibility: hidden;
  z-index: 1;
  top: 100%;
  left: 0%;
  width: 100%;
  color: white;
  font-size: 12px;
  background-color: #2d3d4c;
  border-radius: 10px;
  padding: 10px 15px 10px 15px;
}

#fade {
  opacity: 1;
  transition: opacity 0.5s;
}

#delay {
  opacity: 0;
  transition: opacity 0.2s;
  transition-delay: 1s;
}

td {
  position: relative;
}

tr:hover .tooltip-text {
  display: block;
  visibility: visible;
}

.tr:hover #fade {
  opacity: 1;
}

.tr:hover #delay {
  opacity: 1;
}

.callout {
  padding: 0.5rem 1rem 0.5rem 3rem;
  background: #D9EDF9;
  border: 3px solid #0088D1;
  color: #272eb5;
  position: relative;
  max-width: 40rem;
  border-radius: 10px;
  margin-top: 10%;
  font-size: 11pt;
}

.callout-icon {
  content: "";

  /* SVG via a data URI! */
  background-size: cover;
  width: 1.5rem;
  height: 1.5rem;
  display: block;
  position: absolute;
  left: 0.9rem;
  top: 1.1rem;
}

.callout-icon svg{
  fill: #016ca7;
}
.callout p+p {
  margin-top: 1em;
}

.callout a {
  color: #272eb5;
  font-weight: bold;
}

#gsk-logo {
  padding-top: 10px;
}
</style>
<script src="https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js" integrity="sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf" crossorigin="anonymous"></script>
<script src="https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js" integrity="sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A" crossorigin="anonymous"></script>





<div class="main">
    <div id="gsk-rag" class="dark:text-white dark:bg-zinc-800 rounded border border-gray-500">
        <div class="header border-b border-b-gray-500">
            
                <svg xmlns="http://www.w3.org/2000/svg" width="60" height="30" viewBox="0 0 30 15" fill="none" id="gsk-logo">
                    <path fill="#fff" fill-rule="evenodd"
                        d="M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z"
                        clip-rule="evenodd" />
                </svg>
            <h1>RAG Evaluation Toolkit</h1>
        </div>
        
        <div class="section-container">
            <div class="components-container">
                
                <div class="component-card">
                    <div class="component-title">GENERATOR</div>
                    <div class="component-value tooltip  text-red ">
                        12.0%
                            <span class="tooltiptext" id="fade">The Generator is the LLM inside the RAG to generate the answers.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=12.0 class=" progress-red ">12.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">RETRIEVER</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">REWRITER</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">ROUTING</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Router filters the query of the user based on his intentions (intentions detection).</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">KNOWLEDGE_BASE</div>
                    <div class="component-value tooltip  text-green ">
                        95.71%
                            <span class="tooltiptext" id="fade">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=95.71428571428572 class=" progress-green ">95.71%</progress>
                    </div>
                </div>
                
                <div class="overall-card">
                    <div class="overall-title">Overall Correctness Score</div>
                    <div class="overall-value">12%</div>
                </div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">RECOMMENDATION</div>
                <span class="section-content">Based on the scores, the RAG system needs to focus on improving its performance on complex questions. Implementing better strategies for handling paraphrasing in the Generator component would be a key step to enhance overall system performance.</span>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">CORRECTNESS BY TOPIC</div>
                    <script type="text/javascript">
        (function() {
  const fn = function() {
    Bokeh.safely(function() {
      (function(root) {
        function embed_document(root) {
        const docs_json = '{"f9d8199b-6456-4bb2-af16-36040cf14d2d":{"version":"3.4.3","title":"Bokeh Application","roots":[{"type":"object","name":"Figure","id":"p2418","attributes":{"height":350,"width_policy":"max","x_range":{"type":"object","name":"DataRange1d","id":"p2420","attributes":{"start":0}},"y_range":{"type":"object","name":"FactorRange","id":"p2427","attributes":{"factors":["Medical Products","Others","PROVENGE Treatment"]}},"x_scale":{"type":"object","name":"LinearScale","id":"p2428"},"y_scale":{"type":"object","name":"CategoricalScale","id":"p2429"},"title":{"type":"object","name":"Title","id":"p2425","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p2447","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p2415","attributes":{"selected":{"type":"object","name":"Selection","id":"p2416","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p2417"},"data":{"type":"map","entries":[["correctness",{"type":"ndarray","array":{"type":"bytes","data":"AAAAAAAAKUAkSZIkSZIsQAAAAAAAACRA"},"shape":[3],"dtype":"float64","order":"little"}],["metadata_values",["Medical Products","Others","PROVENGE Treatment"]],["colors",["#def193","#006837","#a50026"]]]}}},"view":{"type":"object","name":"CDSView","id":"p2448","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p2449"}}},"glyph":{"type":"object","name":"HBar","id":"p2444","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"fill_color":{"type":"value","value":"#14191B"}}},"nonselection_glyph":{"type":"object","name":"HBar","id":"p2445","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"line_alpha":{"type":"value","value":0.1},"fill_color":{"type":"value","value":"#14191B"},"fill_alpha":{"type":"value","value":0.1},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"HBar","id":"p2446","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"#14191B"},"fill_alpha":{"type":"value","value":0.2},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p2456","attributes":{"data_source":{"id":"p2415"},"view":{"type":"object","name":"CDSView","id":"p2457","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p2458"}}},"glyph":{"type":"object","name":"HBar","id":"p2453","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"HBar","id":"p2454","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.1},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"HBar","id":"p2455","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.2},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p2466","attributes":{"visible":false,"data_source":{"type":"object","name":"ColumnDataSource","id":"p2460","attributes":{"selected":{"type":"object","name":"Selection","id":"p2461","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p2462"},"data":{"type":"map","entries":[["x",[0]],["y",[0]]]}}},"view":{"type":"object","name":"CDSView","id":"p2467","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p2468"}}},"glyph":{"type":"object","name":"Line","id":"p2463","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_width":2,"line_dash":[6]}},"nonselection_glyph":{"type":"object","name":"Line","id":"p2464","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_alpha":0.1,"line_width":2,"line_dash":[6]}},"muted_glyph":{"type":"object","name":"Line","id":"p2465","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_alpha":0.2,"line_width":2,"line_dash":[6]}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p2426","attributes":{"tools":[{"type":"object","name":"HoverTool","id":"p2440","attributes":{"renderers":"auto","tooltips":[["topic","@metadata_values"],["Correctness","@correctness{0.00}"]]}}]}},"toolbar_location":null,"left":[{"type":"object","name":"CategoricalAxis","id":"p2435","attributes":{"ticker":{"type":"object","name":"CategoricalTicker","id":"p2436"},"formatter":{"type":"object","name":"CategoricalTickFormatter","id":"p2437"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p2438"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p2430","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p2431","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p2432"},"axis_label":"Correctness (%)","axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p2433"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p2434","attributes":{"axis":{"id":"p2430"},"grid_line_color":"#E0E0E0","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p2439","attributes":{"dimension":1,"axis":{"id":"p2435"},"grid_line_color":"#E0E0E0","grid_line_alpha":0.25}},{"type":"object","name":"Span","id":"p2459","attributes":{"location":12.0,"dimension":"height","line_color":"#EA3829","line_width":2,"line_dash":[6]}},{"type":"object","name":"Legend","id":"p2469","attributes":{"border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p2470","attributes":{"label":{"type":"value","value":"Correctness on the entire Testset"},"renderers":[{"id":"p2466"}]}}]}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}]}}';
        const render_items = [{"docid":"f9d8199b-6456-4bb2-af16-36040cf14d2d","roots":{"p2418":"e6d6006b-2dad-4ae6-b903-d76b83278a16"},"root_ids":["p2418"]}];
        root.Bokeh.embed.embed_items(docs_json, render_items);
        }
        if (root.Bokeh !== undefined) {
          embed_document(root);
        } else {
          let attempts = 0;
          const timer = setInterval(function(root) {
            if (root.Bokeh !== undefined) {
              clearInterval(timer);
              embed_document(root);
            } else {
              attempts++;
              if (attempts > 100) {
                clearInterval(timer);
                console.log("Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing");
              }
            }
          }, 10, root)
        }
      })(window);
    });
  };
  if (document.readyState != "loading") fn();
  else document.addEventListener("DOMContentLoaded", fn);
})();
    </script>

                <div id="e6d6006b-2dad-4ae6-b903-d76b83278a16" data-root-id="p2418" style="display: contents;"></div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">KNOWLEDGE BASE OVERVIEW</div>
                    <script type="text/javascript">
        (function() {
  const fn = function() {
    Bokeh.safely(function() {
      (function(root) {
        function embed_document(root) {
        const docs_json = '{"7e4e7d98-6689-46c2-afad-27dcd094f80f":{"version":"3.4.3","title":"Bokeh Application","roots":[{"type":"object","name":"Tabs","id":"p2351","attributes":{"sizing_mode":"stretch_width","tabs":[{"type":"object","name":"TabPanel","id":"p2288","attributes":{"title":"Topic exploration","child":{"type":"object","name":"Figure","id":"p2243","attributes":{"sizing_mode":"stretch_width","x_range":{"type":"object","name":"Range1d","id":"p2252","attributes":{"start":-20.730553102493285,"end":-12.543229675292968}},"y_range":{"type":"object","name":"Range1d","id":"p2253","attributes":{"start":1.8786475658416748,"end":7.937750339508057}},"x_scale":{"type":"object","name":"LinearScale","id":"p2254"},"y_scale":{"type":"object","name":"LinearScale","id":"p2255"},"title":{"type":"object","name":"Title","id":"p2250","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p2283","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p2240","attributes":{"selected":{"type":"object","name":"Selection","id":"p2241","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p2242"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"tv2WwbQgjMFX+ZzBviuQwdO3ksFPNpTBnMONwVseiMEIq5nBvvCgwdt2msH47p/BeoOUwRDco8Fl1p7BNfiawXwlmMHV9JLBAnGNwfyfgsGip4HBpI58wbdTeMGI9ojB"},"shape":[24],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"7BGaQIJpkkCK9pVAGqetQFux3UDm38FAA8rOQI+nu0As5bJAslawQCP70kD0CM1ARPCEQDyrkkAVgXVAJ904QK8JZkBcyz5AuFVDQFDBn0BC/IlAaD9rQJpmlUA9F2tA"},"shape":[24],"dtype":"float32","order":"little"}],["topic",["Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others"]],["id",[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23]],["content",["PROVENGE- sipuleucel-t injection \\n \\nDendreon Pharmaceuticals LLC\\n----------\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\nThese highlights do not include all the information needed to use PROVENGE \\n (sipuleucel-\\nT) safely and effectively. See full prescribing information for PROVENGE. \\nPROVENGE \\n (sipuleucel-T) \\nSuspension for Intravenous Infusion \\nInitial U.S. Approval: 2010\\nRECENT MAJOR CHANGES\\nDosage and Administration\\n     Administration ( \\n2.2\\n)\\n9/2014\\nWarnings and Precautions\\n     Acute Infusion R...","ADVERSE REACTIONS\\nThe most common adverse reactions (incidence \\u2265 15%) are chills, fatigue, fever, back pain, nausea, joint\\nache, and headache. ( \\n6\\n)\\nTo report SUSPECTED ADVERSE REACTIONS, contact Dendreon Pharmaceuticals LLC at 1-\\n877-336-3736 or FDA at 1-800-FDA-1088 or \\nwww.fda.gov/medwatch\\n.\\nSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.\\nRevised: 7/2017\\nFULL PRESCRIBING INFORMATION: CONTENTS\\n*\\n1 INDICATIONS AND USAGE\\n2 DOSAGE AND ADMINISTRATION\\n2.1 Dose\\n2.2 Admi...","PROVENGE \\n (sipuleucel-T) is an autologous cellular immunotherapy indicated for the\\ntreatment of asymptomatic or minimally symptomatic metastatic castrate-resistant\\n(hormone-refractory) prostate cancer.\\n2 DOSAGE AND ADMINISTRATION\\nFor autologous use only.\\nFor intravenous use only.\\n2.1 Dose\\nEach dose of PROVENGE contains a minimum of 50 million autologous CD54 \\n cells\\nactivated with PAP-GM-CSF [ \\nsee Description ( \\n11\\n) \\n].\\nThe recommended course of therapy for PROVENGE is 3 complete doses, given...","3\\n. \\nMatch the patient&#x27;s identity with the patient identifiers on the Final\\nProduct Disposition Notification form and the PROVENGE infusion bag.\\n4\\n. \\nInfuse the entire volume of the PROVENGE infusion bag intravenously over\\napproximately 60 minutes. \\nDo not use a cell filter.\\n5\\n. \\nObserve the patient for acute infusion reactions for at least 30 minutes following\\neach infusion.\\nIf acute infusion reactions occur, such as chills, fatigue, fever, nausea, and joint\\nache, interrupt or slow the infusion...","ache, nausea, and vomiting. The incidence of severe events was greater following the\\nsecond infusion (2.1% vs. 0.8% following the first infusion), and decreased to 1.3%\\nfollowing the third infusion. Some (1.2%) patients in the PROVENGE group were\\nhospitalized within 1 day of infusion for management of acute infusion reactions. No\\nGrade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.\\nIn controlled clinical trials, severe (Grade 3) acute infusion reactions were rep...","Provenge. The clinical significance and causal relationship are uncertain. Most patients\\nhad multiple risk factors for these events. \\nCardiovascular disorders\\n:  In controlled clinical\\ntrials, myocardial infarctions were observed in 0.8% of patients in the PROVENGE group\\ncompared with 0.3% of patients in the control group.  In the postmarketing setting,\\nmyocardial infarctions have been observed following infusion of Provenge. The clinical\\nsignificance and causal relationship are uncertain. Most ...","PROVENGE group who underwent at least 1 leukapheresis procedure in four\\nrandomized, controlled clinical trials. The control group (n = 303) received non-activated\\nautologous peripheral blood mononuclear cells. Patients received 3 infusions of\\nPROVENGE or control every other week over a period of 4 weeks.\\nAlmost all (98.3%) patients in the PROVENGE group and 96% in the control group\\nreported an adverse event. In 67.4% of patients in the PROVENGE group, these adverse\\nevents were mild or moderate i...","Control group received non-activated autologous peripheral blood mononuclear cells.\\nNausea\\n129 (21.5)\\n3 (0.5)\\n45 (14.9)\\n0 (0.0)\\nJoint ache\\n118 (19.6)\\n11 (1.8)\\n62 (20.5)\\n5 (1.7)\\nHeadache\\n109 (18.1)\\n4 (0.7)\\n20 (6.6)\\n0 (0.0)\\nCitrate toxicity\\n89 (14.8)\\n0 (0.0)\\n43 (14.2)\\n0 (0.0)\\nParesthesia\\n85 (14.1)\\n1 (0.2)\\n43 (14.2)\\n0 (0.0)\\nVomiting\\n80 (13.3)\\n2 (0.3)\\n23 (7.6)\\n0 (0.0)\\nAnemia\\n75 (12.5)\\n11 (1.8)\\n34 (11.2)\\n7 (2.3)\\nConstipation\\n74 (12.3)\\n1 (0.2)\\n40 (13.2)\\n3 (1.0)\\nPain\\n74 (12.3)\\n7 (1.2)\\n20 (6.6)\\n3 (1.0)\\n...","The following adverse reactions have been identified during post-approval use of\\nPROVENGE. Because these reactions are reported voluntarily from a population of\\nuncertain size, it is not always possible to reliably estimate their frequency or establish a\\ncausal relationship to drug exposure.\\nNervous system disorders\\n:\\n syncope, transient ischemic attack, strokes [see\\nWarnings and Precautions ( \\n5.1\\n, \\n5.3\\n)]\\nVascular disorders\\n:\\n hypotension [see \\nWarnings and Precautions ( \\n5.1\\n)]\\nCardiovascula...","CSF, consisting of prostatic acid phosphatase (PAP), an antigen expressed in prostate\\ncancer tissue, linked to granulocyte-macrophage colony-stimulating factor (GM-CSF), an\\nimmune cell activator. Each dose of PROVENGE contains a minimum of 50 million\\nautologous CD54 \\n cells activated with PAP-GM-CSF, suspended in 250 mL of Lactated\\nRinger&#x27;s Injection, USP.\\nThe active components of PROVENGE are autologous APCs and PAP-GM-CSF. During\\nculture, the recombinant antigen can bind to and be processed by...","13 NONCLINICAL TOXICOLOGY\\n14 CLINICAL STUDIES\\nThe effect of PROVENGE on patients with metastatic castrate-resistant (hormone-\\nrefractory) prostate cancer was studied in three similar randomized, double-blind,\\nplacebo-controlled, multicenter trials. Following randomization, patients from both\\ntreatment groups underwent a series of 3 leukapheresis procedures (at approximately\\nWeeks 0, 2, and 4). Each leukapheresis was followed approximately 3 days later by\\ninfusion of PROVENGE or control. The cont...","Table 2 Summary of Overall Survival (All Patients as Randomized)\\n Hazard ratio and p-value based on the Cox Model adjusted for PSA (ln) and LDH (ln) and stratified\\nby bisphosphonate use, number of bone metastases, and primary Gleason grade.\\n Hazard ratio based on the unadjusted Cox Model (not pre-specified).\\n p-value based on a log-rank test (not pre-specified).\\nAbbreviations: CI = confidence interval.\\nStudy 1\\nStudy 2\\nPROVENGE \\n(N=341)\\nControl \\n(N=171)\\nPROVENGE\\n(N=82)\\nControl \\n(N=45)\\nOverall Sur...","NDC 30237-8900-6: One bag individually packed in a carton.\\nPROVENGE is shipped directly to the infusing provider in a cardboard shipping box with\\na special insulated polyurethane container inside. The insulated container and gel packs\\nwithin the container are designed to maintain the appropriate transportation and storage\\ntemperature of PROVENGE until infusion.\\nUpon receipt, open the outer cardboard shipping box to verify the product and\\npatient-specific labels located on the top of the insulate...","PROVENGE\\n(sipuleucel-T)\\nThis leaflet is designed to help you understand treatment with PROVENGE (pronounced\\nPROH-venj). The more you understand your treatment, the better you will be able to\\nparticipate in your care. This leaflet does not take the place of talking with your doctor or\\nhealthcare professional about your medical condition or your treatment. If you have any\\nquestions, speak with your doctor.\\nWhat is PROVENGE?\\nPROVENGE is a prescription medicine that is used to treat certain patients...","PROVENGE. Any of these may be signs of heart or lung problems.\\nyou develop numbness or weakness on one side of the body, decreased vision in one\\neye or difficulty speaking. Any of these may be signs of a stroke.\\nyou develop symptoms of thrombosis which may include: pain and/or swelling of an\\narm or leg with warmth over the affected area, discoloration of an arm or leg,\\nunexplained shortness of breath, chest pain that worsens on deep breathing.\\nyou get a fever over 100\\u00baF, or redness or pain at th...","Principal Display Panel \\u2013 Bag Label\\nNDC 30237-8900-5\\nsipuleucel-T\\nPROVENGE \\nRX ONLY FOR AUTOLOGOUS USE ONLY\\nNo U.S. standard of potency\\nCONTENTS: A minimum of 50 million autologous CD54 \\n cells activated with PAP-GM-CSF\\nand suspended in Lactated Ringer&#x27;s Injection, USP.\\nManufactured by:\\nDendreon Pharmaceuticals LLC Seal Beach, CA 90740\\nPhone: 877-256-4545\\nU.S. Lic. # 1749\\nNo preservatives. Gently mix and re-suspend the contents of the bag. 000074.01\\nOne autologous dose for infusion. See package ...","Package Label 2\\nsipuleucel-T 250 mL Lot XXXXXX-X\\nStore Refrigerated 2-8\\u00b0C DO NOT FREEZE\\nExpiration Date: DD-MMM-YYYY\\nExpiration Time: XX:XX Time Zone:\\nFirst Name MI:\\nLast Name:\\nDate of Birth: DD-MMM-YYYY\\nNOT EVALUATED FOR INFECTIOUS SUBSTANCES\\nPROVENGE  \\nsipuleucel-t injection","Product Information\\nProduct Type\\nCELLULAR THERAPY\\nItem Code (Source)\\nNDC:30237-8900\\nRoute of Administration\\nINTRAVENOUS\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nSIPULEUCEL-T\\n (UNII: 8Q622VDR18) \\n(SIPULEUCEL-T - UNII:8Q622VDR18)\\nSIPULEUCEL-T\\n50000000 \\nInactive Ingredients\\nIngredient Name\\nStrength\\nPOTASSIUM CHLORIDE\\n (UNII: 660YQ98I10)\\n \\nCALCIUM CHLORIDE\\n (UNII: M4I0D6VV5M)\\n \\nWATER\\n (UNII: 059QF0KO0R)\\n \\nSODIUM CHLORIDE\\n (UNII: 451W47IQ8X)\\n \\nSODIUM LACTATE\\n (UNII: ...","Dendreon Pharmaceuticals LLC\\nPharmaceuticals LLC\\n968590237\\n, label(30237-8900)\\n \\nRevised: 10/2024","AFRIN NODRIP ALLERGY SINUS NIGHT- oxymetazoline hydrochloride spray \\n \\nBayer HealthCare LLC.\\n----------\\nAfrin NoDrip Allergy Sinus Night UI1612461\\nDrug Facts\\nActive ingredient \\nPurpose\\nOxymetazoline hydrochloride 0.05%\\u2026\\u2026.\\u2026....Nasal decongestant\\nUses\\n\\u25aa \\ntemporarily relieves nasal congestion due to:\\n\\u25aa \\ncommon cold \\n\\u25aahay fever\\n\\u25aa \\nupper respiratory allergies\\n\\u25aa \\nreduces swelling of nasal passages so you can breathe more freely\\n\\u25aa \\ntemporarily relieves sinus congestion and pressure\\nWarnings\\n\\u25aa \\nAsk a do...","supervision): 2 or 3 sprays in each nostril not more often than\\nevery 10 to 12 hours. Do not exceed 2 doses in any 24-hour\\nperiod.\\n\\u25aa children under 6 years of age: ask a doctor\\nTo Use: Shake well before use. Hold white tabs, press grooved area of cap firmly and\\nturn counter clockwise. Before using the first time, prime metered pump by depressing\\npump firmly several times. To spray, hold bottle with thumb at base and nozzle between\\nfirst and second fingers. Without tilting head, insert nozzle int...","Oxymetazoline HCl\\nNasal Solution-Nasal Decongestant\\nAFRIN\\nNODRIP\\nWont drive from nose or down throat\\nAllergy Sinus\\nNight\\nwith soothing chamomile scent\\nPUMP MIST\\nInstant Congestion","Relief from Allergies\\nfor a More Restful Night\\nReduces\\nSwelling of\\nNasal\\nPassages\\n1/2 FL OZ (15mL)\\nAFRIN NODRIP ALLERGY SINUS NIGHT  \\noxymetazoline hydrochloride spray\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:11523-0034\\nRoute of Administration\\nNASAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nOXYMETAZOLINE HYDROCHLORIDE\\n (UNII: K89MJ0S5VY) \\n(OXYMETAZOLINE\\n- UNII:8VLN5B44ZY)\\nOXYMETAZOLINE\\nHYDROCHLORIDE\\n0.5 mg\\n in 1 mL\\nInactive Ingredien...","Bayer HealthCare LLC.\\nMarketing Information\\nMarketing\\nCategory\\nApplication Number or Monograph\\nCitation\\nMarketing Start\\nDate\\nMarketing End\\nDate\\nOTC Monograph Drug\\nM012\\n11/09/2020\\nLabeler - \\nBayer HealthCare LLC. \\n(112117283)\\n \\nRevised: 12/2024"]],["color",{"type":"ndarray","array":["#999","#999","#999","#999","#999","#999","#999","#999","#999","#999","#999","#999","#999","#999","#999","#999","#999","#999","#999","#999","#999","#999","#999","#999"],"shape":[24],"dtype":"object","order":"little"}]]}}},"view":{"type":"object","name":"CDSView","id":"p2284","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p2285"}}},"glyph":{"type":"object","name":"Scatter","id":"p2280","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.7},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p2281","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p2282","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.2}}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p2251","attributes":{"logo":"grey","tools":[{"type":"object","name":"HoverTool","id":"p2266","attributes":{"renderers":"auto","tooltips":"\\n    &lt;div style=\\"width:400px;\\"&gt;\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\n    &lt;/div&gt;\\n    "}},{"type":"object","name":"PanTool","id":"p2267"},{"type":"object","name":"WheelZoomTool","id":"p2268","attributes":{"renderers":"auto"}},{"type":"object","name":"BoxZoomTool","id":"p2269","attributes":{"overlay":{"type":"object","name":"BoxAnnotation","id":"p2270","attributes":{"syncable":false,"level":"overlay","visible":false,"left":{"type":"number","value":"nan"},"right":{"type":"number","value":"nan"},"top":{"type":"number","value":"nan"},"bottom":{"type":"number","value":"nan"},"left_units":"canvas","right_units":"canvas","top_units":"canvas","bottom_units":"canvas","line_color":"black","line_alpha":1.0,"line_width":2,"line_dash":[4,4],"fill_color":"lightgrey","fill_alpha":0.5}}}},{"type":"object","name":"ResetTool","id":"p2275"},{"type":"object","name":"SaveTool","id":"p2276"}]}},"left":[{"type":"object","name":"LinearAxis","id":"p2261","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p2262","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p2263"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p2264"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p2256","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p2257","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p2258"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p2259"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p2260","attributes":{"axis":{"id":"p2256"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p2265","attributes":{"dimension":1,"axis":{"id":"p2261"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Legend","id":"p2286","attributes":{"title":"Knowledge Base Tospics","title_text_color":"#B1B1B1","title_text_font_style":"bold","border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p2287","attributes":{"label":{"type":"value","value":"Others"},"renderers":[{"id":"p2283"}],"index":0}}]}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}}},{"type":"object","name":"TabPanel","id":"p2350","attributes":{"title":"Failures","child":{"type":"object","name":"Figure","id":"p2293","attributes":{"sizing_mode":"stretch_width","x_range":{"type":"object","name":"Range1d","id":"p2302","attributes":{"start":-20.730553102493285,"end":-12.543229675292968}},"y_range":{"type":"object","name":"Range1d","id":"p2303","attributes":{"start":1.8786475658416748,"end":7.937750339508057}},"x_scale":{"type":"object","name":"LinearScale","id":"p2304"},"y_scale":{"type":"object","name":"LinearScale","id":"p2305"},"title":{"type":"object","name":"Title","id":"p2300","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p2332","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p2289","attributes":{"selected":{"type":"object","name":"Selection","id":"p2290","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p2291"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"vvCgwaSOfMEIq5nBfCWYwdt2msG0IIzBNfiawVf5nMG+K5DBWx6IwfyfgsFl1p7B+O6fwZzDjcG2/ZbBiPaIwXqDlMEQ3KPBTzaUwQJxjcG3U3jB1fSSwdO3ksGip4HBtCCMwQ=="},"shape":[25],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"slawQGg/a0As5bJArwlmQCP70kCCaZJAJ904QIr2lUAap61Aj6e7QFDBn0AVgXVA9AjNQAPKzkDsEZpAPRdrQETwhEA8q5JA5t/BQLhVQ0CaZpVAXMs+QFux3UBC/IlAgmmSQA=="},"shape":[25],"dtype":"float32","order":"little"}],["topic",["PROVENGE Treatment","PROVENGE Treatment","Others","PROVENGE Treatment","PROVENGE Treatment","Medical Products","Others","Medical Products","Medical Products","PROVENGE Treatment","PROVENGE Treatment","Others","Others","Others","Medical Products","Medical Products","Others","PROVENGE Treatment","PROVENGE Treatment","Others","Medical Products","PROVENGE Treatment","Medical Products","PROVENGE Treatment","Medical Products"]],["correctness",[false,true,false,false,false,false,false,false,true,false,false,false,false,true,false,false,false,false,false,false,false,false,false,false,false]],["questions",["What are some of the severe acute infusion reactions reported in patients receiving PROVENGE, and how does the incidence of these reactions vary after subsequent infusions?","What are the specific storage conditions recommended for sipuleucel-T and what precaution should be taken regarding freezing?","In the event of acute infusion reactions during the administration of PROVENGE, what specific actions should be taken and what medical treatments can be administered?","What are the components of PROVENGE and in what form is it provided?","What are the handling precautions recommended for healthcare professionals in relation to the potential transmission of infectious diseases while dealing with PROVENGE, and what precautions should be taken regarding the concurrent use of chemotherapy or immunosuppressive agents with PROVENGE?","What are the specific instructions for administering the nasal spray, including the recommended number of sprays per nostril and the frequency of administration?","What were the specific criteria that led to the exclusion of patients in Study 1 of the clinical trials for PROVENGE?","What is the specific brand name of the nasal decongestant solution containing Oxymetazoline HCl and a soothing chamomile scent?","What is the specific active ingredient found in AFRIN NODRIP ALLERGY SINUS NIGHT spray that helps in reducing the swelling of nasal passages?","What is the specific dosage regimen recommended for PROVENGE, and what steps should be taken if a patient misses a scheduled infusion?","What are the components that make up PROVENGE, including the protein designed to trigger an immune response to prostate cancer and the infusion solution in which the product is suspended?","Could you explain in detail the process by which PROVENGE functions in the body to induce an immune response against PAP, an antigen commonly found in prostate cancers, including the role of autologous APCs, PAP-GM-CSF, and the display of small peptides on the APC surface?","What percentage of patients in the PROVENGE group experienced severe (Grade 3) adverse events in the clinical trials?","What are the adverse reactions with an incidence of at least 15% associated with the medication according to the provided document?","What are the specific health conditions that individuals should consult a doctor about before using Afrin NoDrip Allergy Sinus Night spray, and what are the potential consequences of prolonged or excessive use?","What is the specific label number associated with Dendreon Pharmaceuticals LLC mentioned in Document 23?","Can you list the adverse reactions identified during post-approval use, considering the data provided in Document 12?","What specific nervous system disorders have been associated with the post-approval use of PROVENGE, as indicated in the provided document?","What is the recommended dosage regimen for PROVENGE (sipuleucel-T) and what should be done if a patient is unable to receive a scheduled infusion?","What are the potential side effects that are most frequently experienced by individuals receiving PROVENGE, and what serious reactions should prompt immediate medical attention?","What is the name of the active ingredient or active moiety present in the product associated with the item code NDC:30237-8900?","In the scenario where a patient lacks sufficient peripheral venous access for the leukapheresis procedure and PROVENGE infusion, what alternative should be considered and what instructions should be given to the patient regarding this alternative?","When did Bayer HealthCare LLC start marketing the OTC Monograph Drug M012?","What is the specific number of autologous CD54 cells that must be present in each dose of PROVENGE according to the label?","What are the specific instructions for administering the nasal spray, including the number of sprays per nostril, frequency of use, and any precautions to be taken?"]],["agent_answer",["According to the FDA-approved prescribing information for PROVENGE (sipuleucel-T), a severe acute infusion reaction is a serious allergic reaction that can occur within 30 minutes of starting an infusion. Some of the severe acute infusion reactions reported in patients receiving PROVENGE include:\\n\\n1. Anaphylaxis: A life-threatening allergic reaction characterized by symptoms such as difficulty breathing, rapid heartbeat, and swelling of the face or lips.\\n2. Hypotension: A sudden drop in blood pressure that can lead to dizziness, fainting, or even loss of consciousness.\\n3. Bronchospasm: Constriction of the airways that can cause wheezing, coughing, and shortness of breath.\\n4. Throat swelling: Swelling of the throat and vocal cords that can obstruct breathing.\\n\\nThe incidence of severe acute infusion reactions decreases with subsequent infusions. According to a clinical trial conducted by Dendreon Corporation (the manufacturer of PROVENGE), the incidence of severe acute infusion reactions was:\\n\\n* 1.2% in the first infusion\\n* 0.6% in the second infusion\\n* 0.3% in the third infusion\\n* Less than 0.5% for subsequent infusions\\n\\nIn this clinical trial, only one patient (out of approximately 500 patients) experienced anaphylaxis during any infusion. This suggests that while severe acute infusion reactions are a potential risk with PROVENGE, they are relatively rare and tend to decrease in frequency after the first few infusions.\\n\\nIt is essential for healthcare providers to carefully monitor patients receiving PROVENGE and have access to emergency medical services in case of an adverse reaction.","According to the FDA-approved labeling and manufacturer&#x27;s instructions, the specific storage conditions recommended for sipuleucel-T (Provenge) are:\\n\\n* Store at 2\\u00b0C to 8\\u00b0C (36\\u00b0F to 46\\u00b0F).\\n* Do not freeze.\\n\\nIt is crucial to follow these storage guidelines to ensure the integrity and potency of sipuleucel-T. Freezing or temperatures outside the recommended range may affect the product&#x27;s quality, efficacy, or safety.\\n\\nIn addition to proper storage conditions, healthcare professionals should also take precautions when handling and storing sipuleucel-T, including:\\n\\n* Handling with sterile gloves to minimize contamination.\\n* Using aseptic techniques during preparation and administration.\\n* Following proper reconstitution procedures for the vaccine.\\n* Monitoring expiration dates and discarding any expired or compromised product.\\n\\nProper storage and handling of sipuleucel-T are essential to ensure patient safety and optimize therapeutic outcomes.","As a healthcare professional, when administering PROVENGE (sipuleucel-T) to patients, it is essential to monitor them closely for acute infusion reactions. If an infusion reaction occurs, the following steps should be taken:\\n\\n**Specific Actions:**\\n\\n1. **Stop the infusion**: Immediately stop the infusion of PROVENGE.\\n2. **Evaluate the patient**: Assess the patient&#x27;s vital signs and observe their condition.\\n3. **Provide supportive care**: Administer oxygen therapy, if necessary, and consider using antihistamines or corticosteroids to help alleviate symptoms.\\n\\n**Medical Treatments:**\\n\\n1. **Epinephrine**: If the reaction is severe and life-threatening, administer epinephrine according to standard medical practice.\\n2. **Antihistamines**: Administer an antihistamine, such as diphenhydramine or chlorpheniramine, in accordance with the patient&#x27;s medical history and current symptoms.\\n3. **Corticosteroids**: Consider administering a corticosteroid, such as methylprednisolone or prednisone, to help reduce inflammation and alleviate symptoms.\\n\\n**Monitoring:**\\n\\n1. **Vital signs**: Monitor the patient&#x27;s vital signs, including heart rate, blood pressure, respiratory rate, and oxygen saturation.\\n2. **Symptom assessment**: Continuously assess the patient&#x27;s symptoms, such as rash, urticaria, angioedema, or anaphylaxis.\\n\\n**Prevention:**\\n\\nTo minimize the risk of acute infusion reactions during PROVENGE administration:\\n\\n1. **Thoroughly review patient history**: Ensure that patients have no known allergy to any of the components in PROVENGE.\\n2. **Monitor patients closely**: Closely monitor patients during and after infusions, especially those with a history of hypersensitivity or allergic reactions.\\n3. **Follow standard infusion procedures**: Follow established infusion procedures and guidelines for administering PROVENGE.\\n\\nRemember that prompt recognition and treatment of acute infusion reactions are crucial to ensuring patient safety and minimizing the risk of complications.","Provenge, also known as sipuleucel-T, is a cancer vaccine used to treat advanced prostate cancer. The components of Provenge include:\\n\\n* Sipuleucel-T: A type of autologous cellular immunotherapy that uses a patient&#x27;s own immune cells to target and kill prostate cancer cells.\\n* Prolonged Release (P) antigen-presenting cells (APCs): These are immune cells that present antigens to T-cells, helping them recognize and respond to the presence of cancer cells.\\n* Anti-PSA antibody: This is an antibody that targets and binds to prostate-specific antigen (PSA), a protein produced by prostate cells.\\n\\nProvenge is provided in the form of a prescription medication that must be prepared by a healthcare provider. The treatment involves the following steps:\\n\\n1. Blood draw: A patient&#x27;s blood is drawn, and the white blood cells called antigen-presenting cells are isolated.\\n2. Processing: The APCs are then processed to remove any remaining red blood cells and other debris.\\n3. Activation: The APCs are activated with an antibody that targets prostate-specific antigen (PSA), which helps them recognize and respond to prostate cancer cells.\\n4. Infusion: The activated APCs are then infused back into the patient&#x27;s bloodstream, where they can help target and kill prostate cancer cells.\\n\\nProvenge is administered through a series of three infusions, each lasting about 2-3 hours.","According to the manufacturer&#x27;s guidelines and scientific literature, the following handling precautions are recommended for healthcare professionals when working with Provenge (Sipuleucel-T), a therapeutic cancer vaccine:\\n\\n**Handling Precautions:**\\n\\n1. **Personal Protective Equipment (PPE)**: Wear PPE including gloves, gown, mask, and eye protection to minimize exposure to potential biohazards.\\n2. **Containment**: Handle the product in a biologically contained environment or using proper containment techniques to prevent aerosolization or splashing.\\n3. **Sterile Technique**: Follow sterile technique when handling the product to prevent contamination.\\n4. **Waste Management**: Dispose of any contaminated waste, including used gloves and supplies, according to local regulations and guidelines.\\n\\n**Concurrent Use with Chemotherapy or Immunosuppressive Agents:**\\n\\n1. **Assess Risks and Benefits**: Carefully weigh the potential risks and benefits of combining Provenge with chemotherapy or immunosuppressive agents.\\n2. **Monitor Patients Closely**: Monitor patients receiving concurrent therapy for signs of infection, anemia, neutropenia, or thrombocytopenia, which may be exacerbated by Provenge.\\n3. **Adjust Dose or Discontinue**: Adjust the dose of Provenge or discontinue it if the patient experiences severe adverse reactions or if the benefits of treatment outweigh the risks.\\n\\nIt is essential for healthcare professionals to follow these precautions and guidelines when handling Provenge to minimize the risk of infectious disease transmission and optimize patient care.","I&#x27;m happy to help!\\n\\nFor the nasal spray, the specific instructions are as follows:\\n\\n**Administering the Nasal Spray**\\n\\n1. **Number of Sprays**: Use 2-3 sprays per nostril, totaling 4-6 sprays in each nostril.\\n2. **Frequency of Administration**: Administer the nasal spray as needed or as directed by your healthcare provider.\\n\\n**Additional Tips**\\n\\n* Tilt your head back slightly and insert the nozzle into one nostril.\\n* Spray gently and evenly into the nostril, aiming for the inner corner of the nose.\\n* Remove the nozzle and repeat on the other side.\\n* If you experience any discomfort or irritation during or after use, stop using the nasal spray and consult with your healthcare provider.\\n\\nRemember to always follow the instructions provided by your healthcare provider or the product&#x27;s label. If you have any questions or concerns, don&#x27;t hesitate to ask!","According to the study publication (BYR-15, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sipuleucel-T, a Novel Autologous Cellular Immunotherapy, in Men with Hormone-Refractory Metastatic Castration-Resistant Prostate Cancer), the specific criteria for exclusion from Study 1 (also known as BYR-15) were:\\n\\n* Patients with active or worsening neurological symptoms, such as stroke, spinal cord compression, or peripheral neuropathy.\\n* Patients with a history of or current central nervous system (CNS) metastasis (brain or spine).\\n* Patients who had undergone major surgery within the past 30 days.\\n* Patients with a platelet count &lt; 25,000/\\u03bcL.\\n* Patients with an absolute neutrophil count (ANC) &lt; 500/\\u03bcL.\\n* Patients with a bilirubin level &gt; 3 times the upper limit of normal (ULN).\\n* Patients with aspartate transaminase (AST) or alanine transaminase (ALT) levels &gt; 5 times ULN.\\n* Patients who had received prior chemotherapy, except for adjuvant therapy completed more than 6 months before enrollment.\\n\\nThese exclusion criteria were intended to minimize risks associated with the autologous cellular immunotherapy, Sipuleucel-T (PROVENGE), and ensure patient safety during the clinical trial.","The specific brand name of the nasal decongestant solution containing Oxymetazoline HCl and a soothing chamomile scent is Dristernil.","The specific active ingredient found in Afrin Nasal Spray (Nodrip Allergy Sinus Night) that helps reduce swelling of nasal passages is Oxymetazoline Hydrochloride. It is a topical decongestant that works by shrinking blood vessels and reducing swelling in the nasal passages, providing temporary relief from congestion and sinus pressure.","According to the FDA-approved labeling and clinical guidelines, the specific dosage regimen recommended for PROVENGE (sipuleucel-T) is as follows:\\n\\n**Dosage Regimen:**\\n\\n* PROVENGE is administered intradefensively (directly into the seminal vesicles) on two occasions, 2 weeks apart.\\n* Each infusion consists of a 1-hour leukapheresis procedure, followed by manufacturing and formulation of the autologous antigen-presenting cells (APCs) with PA2024 (a recombinant PSA-based vaccine).\\n* The resulting PROVENGE product is then reinfused into the patient within 3 hours of completion of the leukapheresis procedure.\\n\\n**If a Patient Misses a Scheduled Infusion:**\\n\\n* If a patient misses a scheduled infusion, their healthcare provider should reassess the potential risks and benefits of continuing with the treatment regimen.\\n* The missed infusion should not be repeated. Instead, the patient should receive the next scheduled infusion as soon as possible.\\n* The patient&#x27;s healthcare provider may consider adjusting the dosing schedule to minimize delays in completing the two-infusion regimen.\\n\\nIt is essential for patients and their healthcare providers to discuss any questions or concerns about PROVENGE administration, including missed infusions, to ensure proper management of the treatment.","PROVENGE (sipuleucel-T) is a therapeutic cancer vaccine used to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The components that make up PROVENGE are:\\n\\n1. **Protein designed to trigger an immune response to prostate cancer:** Sipuleucel-T is a autologous cellular immunotherapy, which means it&#x27;s made from the patient&#x27;s own cells. The protein component is derived from a protein called PAP (prostatic acid phosphatase), which is found on the surface of prostate cancer cells. The PAP antigen is processed by dendritic cells, leading to an immune response against prostate cancer cells.\\n2. **Infusion solution:** PROVENGE is suspended in a sterile solution of Dulbecco&#x27;s Modified Eagle Medium (DMEM) containing 10% autologous patient-drawn blood and 1% sodium citrate.\\n\\nThe manufacturing process involves the following steps:\\n\\n* Patients receive a leukapheresis procedure to collect their white blood cells (leukocytes).\\n* The collected leukocytes are then processed to remove all but the dendritic cells.\\n* The dendritic cells are activated with PAP antigen, which is derived from the patient&#x27;s own prostate cancer cells.\\n* The activated dendritic cells are mixed with the infusion solution containing autologous patient-drawn blood and sodium citrate.\\n\\nThe resulting product, PROVENGE, is a customized, autologous cellular immunotherapy that is infused back into the patient to stimulate an immune response against prostate cancer cells.","What a fantastic question!\\n\\nProvenge, also known as Sipuleucel-T, is a therapeutic cancer vaccine that harnesses the power of the immune system to attack prostate cancer cells. It&#x27;s an autologous dendritic cell-based immunotherapy, meaning it uses a patient&#x27;s own immune cells to fight their tumor.\\n\\nHere&#x27;s how Provenge works:\\n\\n**Step 1: Isolation of Autologous Antigen-Presenting Cells (APCs)**\\nThe process begins with the isolation of autologous APCs, such as dendritic cells, from the patient&#x27;s blood. These APCs are responsible for processing and presenting antigens to T-cells, which then become activated to attack specific targets.\\n\\n**Step 2: Processing of Prostatic Acid Phosphatase (PAP) Antigen**\\nThe isolated APCs are then exposed to PAP, a tumor-associated antigen commonly found in prostate cancer cells. The PAP antigen is processed by the APCs into smaller peptides, which are then presented on their surface.\\n\\n**Step 3: Activation of Immune Response through PAP-GM-CSF**\\nThe processed PAP peptides are displayed on the surface of the APCs alongside a protein called Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). This combination triggers an immune response by activating T-cells to recognize and attack prostate cancer cells expressing PAP.\\n\\n**Step 4: Display of Small Peptides on APC Surface**\\nThe APCs with processed PAP peptides on their surface can now present these small peptides to T-cells, which are programmed to recognize and respond to specific antigens. This process is known as antigen presentation.\\n\\n**How Autologous APCs Enhance the Immune Response**\\nAutologous APCs play a crucial role in enhancing the immune response by:\\n\\n1. Processing and presenting PAP antigens: Autologous APCs process and present the PAP antigens to T-cells, which then become activated to attack prostate cancer cells.\\n2. Providing co-stimulation: The combination of PAP peptides and GM-CSF on the surface of autologous APCs provides a strong co-stimulatory signal, enhancing the activation and proliferation of T-cells.\\n\\n**The Result: A Specific Immune Response against Prostate Cancer Cells**\\nProvenge induces a specific immune response by activating T-cells to recognize and attack prostate cancer cells expressing PAP. This results in the elimination or inhibition of tumor growth, ultimately leading to improved patient outcomes.\\n\\nIn summary, Provenge works by isolating autologous APCs, processing and presenting PAP antigens, activating an immune response through PAP-GM-CSF, and displaying small peptides on the APC surface to stimulate a specific T-cell response against prostate cancer cells.","According to the PROVENGE (Sipuleucel-T) clinical trial results, approximately 17.4% of patients in the PROVENGE group experienced severe (Grade 3) adverse events.\\n\\nSource: Data on File, Dendreon Corporation. PROVENGE (Sipuleucel-T) prescribing information.","I&#x27;m ready! Please provide the document or information about the medication, and I&#x27;ll help you identify the adverse reactions with an incidence of at least 15%.","**Important Information for Safe Use**\\n\\nBefore using Afrin NoDrip Allergy Sinus Night spray, it&#x27;s essential to consult a doctor if you have any of the following health conditions:\\n\\n1. **Glaucoma**: The ingredients in Afrin can increase eye pressure, which may worsen glaucoma.\\n2. **Allergies or sensitivity to phenylephrine or oxymetazoline**: If you experience an allergic reaction or sensitivity to these ingredients, consult your doctor before using Afrin.\\n3. **Pregnancy or breastfeeding**: While the short-term use of Afrin is generally considered safe during pregnancy and breastfeeding, it&#x27;s crucial to discuss any concerns with your healthcare provider.\\n4. **Heart problems**, such as high blood pressure or heart rhythm disorders: The increased blood pressure caused by Afrin may exacerbate these conditions.\\n\\n**Potential Consequences of Prolonged or Excessive Use**\\n\\nIf you use Afrin NoDrip Allergy Sinus Night spray excessively or for an extended period, you may experience:\\n\\n1. **Rebound congestion**: Your body may adapt to the decongestant effects of Afrin, leading to even more nasal congestion when you stop using it.\\n2. **Nasal dependence**: You may develop a physical dependence on Afrin, making it difficult to stop using it without experiencing withdrawal symptoms like headaches or fatigue.\\n3. **Increased blood pressure**: Long-term use can lead to increased blood pressure, which may worsen existing heart conditions or increase the risk of cardiovascular problems.\\n\\n**Safe Use Recommendations**\\n\\nTo minimize risks and ensure safe use:\\n\\n1. Follow the recommended dosage instructions on the label.\\n2. Only use Afrin as directed for a maximum of 3-5 days in a row.\\n3. If your symptoms persist or worsen, consult your doctor for further guidance.\\n4. Consider alternative decongestant products if you experience rebound congestion or nasal dependence.\\n\\nRemember to always read and follow the label instructions, and consult your doctor if you have any concerns about using Afrin NoDrip Allergy Sinus Night spray.","Based on the provided information, I found that in Document 23, the specific label number associated with Dendreon Pharmaceuticals LLC is:\\n\\n**Label Number: 2075**\\n\\nPlease let me know if you&#x27;d like me to clarify or provide more context about this finding.","I&#x27;m not a medical professional, so I can&#x27;t answer your question. If you have concerns about the safety of any medication, consult with your healthcare provider or a qualified pharmacist.","According to the FDA-approved labeling for PROVENGE (sipuleucel-T), there are several nervous system disorders that have been reported during its post-approval use. These include:\\n\\n1. Seizures: Reports of seizures, including grand mal and partial seizures, were observed in patients receiving PROVENGE.\\n2. Hypokalemia and muscle weakness: Cases of hypokalemia (low potassium levels) and muscle weakness have been reported, which may be related to the immune response triggered by PROVENGE.\\n3. Peripheral neuropathy: Some patients experienced peripheral neuropathy, characterized by numbness, tingling, or pain in their extremities.\\n4. Demyelinating polyneuropathy: A few cases of demyelinating polyneuropathy, a condition that affects the protective covering around nerve fibers (myelin), have been reported.\\n\\nThese nervous system disorders were reported at an incidence rate of 1-5% or less in patients receiving PROVENGE as part of clinical trials. However, it is essential to note that these events may not be directly caused by PROVENGE and may be related to underlying medical conditions or other factors.","According to the FDA-approved labeling, the recommended dosage regimen for PROVENGE (sipuleucel-T) is as follows:\\n\\n**Recommended Dosage Regimen:**\\n\\n* Each treatment cycle consists of three infusions:\\n\\t+ Infusion 1: Given on Day 3 after leukapheresis\\n\\t+ Infusion 2: Given on Day 10 after leukapheresis\\n\\t+ Infusion 3: Given on Day 17 after leukapheresis\\n* The infusion process typically takes approximately 2 hours.\\n* Patients should receive a minimum of three cycles, with each cycle separated by at least 2 weeks.\\n\\n**What to do if a patient is unable to receive a scheduled infusion:**\\n\\nIf a patient is unable to receive a scheduled infusion, the following steps can be taken:\\n\\n1. **Contact the healthcare provider:** Notify the healthcare provider immediately if the patient is unable to receive an infusion.\\n2. **Modify the treatment schedule:** If possible, modify the treatment schedule to accommodate the patient&#x27;s needs and ensure that the minimum of three cycles is completed.\\n3. **Consult with a healthcare provider:** Consult with a healthcare provider or a urologist for guidance on how to manage the situation.\\n\\nRemember to always follow the FDA-approved labeling and consult with a healthcare provider if you have any questions or concerns about administering PROVENGE (sipuleucel-T) to patients.","PROVENGE (sipuleucel-T) is a therapeutic cancer vaccine used to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. Common potential side effects of PROVENGE include:\\n\\n1. Infusion-related reactions: These can be mild, moderate, or severe and may occur within 1 hour after infusion. Symptoms can include:\\n\\t* Flu-like symptoms such as fever, chills, nausea, vomiting, headache, and fatigue\\n\\t* Allergic reactions like hives, itching, and swelling\\n\\t* Cardiovascular reactions including hypotension (low blood pressure), hypertension (high blood pressure), tachycardia (rapid heartbeat), and bradycardia (slow heartbeat)\\n2. Fatigue: Feeling tired or lacking energy is a common side effect.\\n3. Chills: Some individuals may experience chills after receiving PROVENGE.\\n4. Headache: Mild to moderate headaches can occur.\\n5. Muscle pain: Pain in the muscles, particularly in the back and arms, can occur.\\n\\nSerious reactions that require immediate medical attention include:\\n\\n1. Anaphylaxis: A severe allergic reaction characterized by:\\n\\t* Difficulty breathing\\n\\t* Swelling of the face, lips, tongue, or throat\\n\\t* Dizziness or fainting\\n\\t* Rapid heartbeat or palpitations\\n2. Cardiovascular events: Symptoms such as chest pain, shortness of breath, or severe hypertension can indicate a serious cardiovascular reaction.\\n3. Severe allergic reactions: Other signs of a severe allergic reaction include:\\n\\t* Difficulty speaking or swallowing\\n\\t* Swelling of the eyes, face, or lips\\n\\t* Hives or itching (in addition to other symptoms)\\n\\nIt is essential for individuals receiving PROVENGE to monitor their condition closely and seek immediate medical attention if they experience any of these serious reactions.","A pharmaceutical question!\\n\\nAccording to the National Drug Code (NDC) database, the item code NDC: 30237-8900 corresponds to the product \\"Seroquel XR\\" (Quetiapine Fumarate Extended Release Tablets).\\n\\nThe active ingredient or active moiety present in this product is Quetiapine Fumarate.\\n\\nPlease note that this information is publicly available and sourced from official databases. If you have any specific concerns or questions, I&#x27;ll be happy to help!","In the scenario where a patient lacks sufficient peripheral venous access for the leukapheresis procedure and PROVENGE infusion, an alternative that should be considered is central venous catheter (CVC) placement.\\n\\nInstructions that should be given to the patient regarding this alternative include:\\n\\n1. The need for CVC placement to ensure safe and effective completion of the leukapheresis procedure and PROVENGE infusion.\\n2. A detailed explanation of the benefits and risks associated with CVC placement, including the potential for infection, bleeding, and discomfort during insertion.\\n3. Information about the types of CVCs that can be used (e.g., percutaneous or surgical), their characteristics, and the potential complications that may arise.\\n4. The importance of maintaining aseptic technique during the procedure to minimize the risk of infection.\\n5. Instructions on how to care for the CVC after placement, including dressing changes, site cleaning, and monitoring for signs of infection.\\n6. A discussion about the potential impact of CVC placement on the patient&#x27;s quality of life, including any limitations or restrictions that may be necessary during the treatment period.\\n\\nIt is essential to involve the patient in the decision-making process and ensure they understand the alternative options, benefits, and risks involved with CVC placement. This will help them make an informed decision about their care and minimize potential complications.\\n\\nReferences:\\n\\n* National Institute of Allergy and Infectious Diseases. (2019). PROVENGE (Sipuleucel-T) Package Insert.\\n* American Society of Hematology. (2020). Leukapheresis: A Guide for Patients and Families.\\n* Centers for Disease Control and Prevention. (2020). Central Venous Catheter-Related Infections: Clinical Practice Guidelines.","According to publicly available information, Bayer HealthCare LLC started marketing the OTC Monograph Drug M012 (Acetaminophen Tablets, USP) in 1988. Would you like me to provide more details or context about this product?","According to the Provenge (Sipuleucel-T) product label, each dose of Provenge must contain at least 50 million autologous CD54+ cells.","The nasal spray instructions!\\n\\n**Product:** XYZ Nasal Spray (Allergic Rhinitis Relief)\\n\\n**Specific Instructions:**\\n\\n1. **Administration:**\\n\\t* Shake the nasal spray bottle well before each use.\\n\\t* Tilt your head slightly forward and insert the nozzle into one nostril.\\n\\t* Gently press the nozzle to release 1-2 sprays into the nostril (see \\"Number of Sprays\\" below).\\n\\t* Repeat on the other side by tilting your head in the opposite direction.\\n2. **Number of Sprays:**\\n\\t* For adults and children aged 6 years and above, use 1 spray per nostril (total of 2 sprays).\\n\\t* For children under 6 years old, consult with a healthcare professional for proper dosage guidance.\\n3. **Frequency of Use:**\\n\\t* Use the nasal spray as needed, up to 3 times daily, or as directed by your healthcare provider.\\n4. **Precautions:**\\n\\t* Wash your hands before and after use.\\n\\t* Avoid touching the nozzle or applicator tip to any surface or object.\\n\\t* Do not share the nasal spray with others or use it if you have a perforated septum or other nasal passage issues.\\n\\t* If symptoms worsen or do not improve within 3 days, consult your healthcare provider for further guidance.\\n\\n**Additional Tips:**\\n\\n* Use the nasal spray at the same time each day to help maintain consistent relief from allergic rhinitis symptoms.\\n* If you experience any unusual side effects, such as bleeding, discharge, or increased nasal secretions, stop using the product and consult with a healthcare professional.\\n\\nRemember to always follow the product label instructions and consult your healthcare provider if you have any questions or concerns."]],["reference_answer",["In patients receiving PROVENGE, some of the acute infusion reactions reported include chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting.","The storage recommendation for sipuleucel-T is to store it refrigerated between 2-8\\u00b0C and to not freeze it.","If acute infusion reactions occur during the administration of PROVENGE, such as chills, fatigue, fever, nausea, and joint ache, the infusion should be interrupted or slowed down. Appropriate medical treatment should be administered as needed. In controlled clinical trials, symptoms of acute infusion reactions were treated with acetaminophen, intravenous H1 and/or H2 blockers, and low-dose intravenous meperidine.","PROVENGE is a 250 mL suspension containing a minimum of 50 million autologous CD54 cells activated with PAP-GM-CSF in Lactated Ringer&#x27;s Injection, USP. It is supplied in a sealed infusion bag labeled for the specific recipient.","The most common adverse reactions reported in clinical trials for PROVENGE were chills, fatigue, fever, back pain, nausea, joint ache, and headache.","The nasal spray should be administered by shaking well before use, holding the bottle with the thumb at the base and the nozzle between the first and second fingers, inserting the nozzle into the nostril without tilting the head, fully depressing the rim with a firm, even stroke, and sniffing deeply. The nozzle should be wiped clean after use, and the cap should be secured.","The exclusion criteria for patients in Study 1 of the clinical trials for PROVENGE included visceral (liver, lung, or brain) metastases, moderate to severe prostate cancer-related pain, and use of narcotics for cancer-related pain.","The brand name of the nasal decongestant solution with a soothing chamomile scent is AFRIN NODRIP.","The active ingredient in AFRIN NODRIP ALLERGY SINUS NIGHT spray is Oxymetazoline Hydrochloride, with a strength of 0.5 mg in 1 mL.","The recommended course of therapy for PROVENGE is 3 complete doses, given at approximately 2-week intervals.","The active components of PROVENGE are the patient&#x27;s own immune cells mixed with a protein designed to create an immune response to prostate cancer. Additionally, the product is suspended in an infusion solution called Lactated Ringer&#x27;s Injection, USP.","PROVENGE is classified as an autologous cellular immunotherapy designed to induce an immune response targeted against PAP, an antigen expressed in most prostate cancers. During ex vivo culture with PAP-GM-CSF, APCs take up and process the recombinant target antigen into small peptides that are then displayed on the APC surface.","23.6% of patients in the PROVENGE group reported severe (Grade 3) adverse events.","The most common adverse reactions (incidence \\u2265 15%) are chills, fatigue, fever, back pain, nausea, joint ache, and headache.","Before using Afrin NoDrip Allergy Sinus Night spray, it is important to ask a doctor if you have heart disease, high blood pressure, thyroid disease, diabetes, or trouble urinating due to an enlarged prostate gland. Additionally, do not use more than directed, do not use for more than 3 days, and avoid using the container by more than one person to prevent the spread of infection.","The label number for Dendreon Pharmaceuticals LLC is 30237-8900.","The adverse reactions identified during post-approval use include nausea, joint ache, headache, citrate toxicity, paresthesia, vomiting, anemia, constipation, pain, paresthesia oral, pain in extremity, dizziness, muscle ache, asthenia, diarrhea, influenza-like illness, musculoskeletal pain, dyspnea, edema peripheral, hot flush, hematuria, muscle spasms, hypertension, anorexia, bone pain, upper respiratory tract infection, insomnia, musculoskeletal chest pain, cough, neck pain, weight decreased, urinary tract infection, rash, sweating, and tremor.","Some of the nervous system disorders associated with the post-approval use of PROVENGE include syncope, transient ischemic attack, and strokes.","The recommended course of therapy for PROVENGE is 3 complete doses, given at approximately 2-week intervals.","The most common side effects of PROVENGE include chills, fatigue, fever, back pain, nausea, joint ache, and headache.","The active ingredient in the product with item code NDC:30237-8900 is SIPULEUCEL-T.","If the patient does not have adequate peripheral venous access, they should be informed about the need for a central venous catheter. The patient should be counseled on the importance of catheter care and instructed to report any signs of infection such as fevers, swelling, or redness around the catheter site.","The marketing start date for the OTC Monograph Drug M012 by Bayer HealthCare LLC is 11/09/2020.","Each dose of PROVENGE contains a minimum of 50 million autologous CD54 cells activated with PAP-GM-CSF.","To use the nasal spray, shake well before use. Hold the white tabs, press the grooved area of the cap firmly and turn it counter clockwise. Before the first use, prime the metered pump by depressing it firmly several times. To spray, hold the bottle with your thumb at the base and the nozzle between your first and second fingers. Without tilting your head, insert the nozzle into your nostril, fully depress the rim with a firm, even stroke, and sniff deeply. Remember to wipe the nozzle clean after use and secure the cap."]],["id",[9,21,8,16,10,1,15,2,3,7,19,14,11,6,0,23,12,13,5,18,22,17,4,20,1]],["content",["CSF, consisting of prostatic acid phosphatase (PAP), an antigen expressed in prostate\\ncancer tissue, linked to granulocyte-macrophage colony-stimulating factor (GM-CSF), an\\nimmune cell activator. Each dose of PROVENGE contains a minimum of 50 million\\nautologous CD54 \\n cells activated with PAP-GM-CSF, suspended in 250 mL of Lactated\\nRinger&#x27;s Injection, USP.\\nThe active components of PROVENGE are autologous APCs and PAP-GM-CSF. During\\nculture, the recombinant antigen can bind to and be processed by...","Oxymetazoline HCl\\nNasal Solution-Nasal Decongestant\\nAFRIN\\nNODRIP\\nWont drive from nose or down throat\\nAllergy Sinus\\nNight\\nwith soothing chamomile scent\\nPUMP MIST\\nInstant Congestion","The following adverse reactions have been identified during post-approval use of\\nPROVENGE. Because these reactions are reported voluntarily from a population of\\nuncertain size, it is not always possible to reliably estimate their frequency or establish a\\ncausal relationship to drug exposure.\\nNervous system disorders\\n:\\n syncope, transient ischemic attack, strokes [see\\nWarnings and Precautions ( \\n5.1\\n, \\n5.3\\n)]\\nVascular disorders\\n:\\n hypotension [see \\nWarnings and Precautions ( \\n5.1\\n)]\\nCardiovascula...","Package Label 2\\nsipuleucel-T 250 mL Lot XXXXXX-X\\nStore Refrigerated 2-8\\u00b0C DO NOT FREEZE\\nExpiration Date: DD-MMM-YYYY\\nExpiration Time: XX:XX Time Zone:\\nFirst Name MI:\\nLast Name:\\nDate of Birth: DD-MMM-YYYY\\nNOT EVALUATED FOR INFECTIOUS SUBSTANCES\\nPROVENGE  \\nsipuleucel-t injection","13 NONCLINICAL TOXICOLOGY\\n14 CLINICAL STUDIES\\nThe effect of PROVENGE on patients with metastatic castrate-resistant (hormone-\\nrefractory) prostate cancer was studied in three similar randomized, double-blind,\\nplacebo-controlled, multicenter trials. Following randomization, patients from both\\ntreatment groups underwent a series of 3 leukapheresis procedures (at approximately\\nWeeks 0, 2, and 4). Each leukapheresis was followed approximately 3 days later by\\ninfusion of PROVENGE or control. The cont...","ADVERSE REACTIONS\\nThe most common adverse reactions (incidence \\u2265 15%) are chills, fatigue, fever, back pain, nausea, joint\\nache, and headache. ( \\n6\\n)\\nTo report SUSPECTED ADVERSE REACTIONS, contact Dendreon Pharmaceuticals LLC at 1-\\n877-336-3736 or FDA at 1-800-FDA-1088 or \\nwww.fda.gov/medwatch\\n.\\nSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.\\nRevised: 7/2017\\nFULL PRESCRIBING INFORMATION: CONTENTS\\n*\\n1 INDICATIONS AND USAGE\\n2 DOSAGE AND ADMINISTRATION\\n2.1 Dose\\n2.2 Admi...","Principal Display Panel \\u2013 Bag Label\\nNDC 30237-8900-5\\nsipuleucel-T\\nPROVENGE \\nRX ONLY FOR AUTOLOGOUS USE ONLY\\nNo U.S. standard of potency\\nCONTENTS: A minimum of 50 million autologous CD54 \\n cells activated with PAP-GM-CSF\\nand suspended in Lactated Ringer&#x27;s Injection, USP.\\nManufactured by:\\nDendreon Pharmaceuticals LLC Seal Beach, CA 90740\\nPhone: 877-256-4545\\nU.S. Lic. # 1749\\nNo preservatives. Gently mix and re-suspend the contents of the bag. 000074.01\\nOne autologous dose for infusion. See package ...","PROVENGE \\n (sipuleucel-T) is an autologous cellular immunotherapy indicated for the\\ntreatment of asymptomatic or minimally symptomatic metastatic castrate-resistant\\n(hormone-refractory) prostate cancer.\\n2 DOSAGE AND ADMINISTRATION\\nFor autologous use only.\\nFor intravenous use only.\\n2.1 Dose\\nEach dose of PROVENGE contains a minimum of 50 million autologous CD54 \\n cells\\nactivated with PAP-GM-CSF [ \\nsee Description ( \\n11\\n) \\n].\\nThe recommended course of therapy for PROVENGE is 3 complete doses, given...","3\\n. \\nMatch the patient&#x27;s identity with the patient identifiers on the Final\\nProduct Disposition Notification form and the PROVENGE infusion bag.\\n4\\n. \\nInfuse the entire volume of the PROVENGE infusion bag intravenously over\\napproximately 60 minutes. \\nDo not use a cell filter.\\n5\\n. \\nObserve the patient for acute infusion reactions for at least 30 minutes following\\neach infusion.\\nIf acute infusion reactions occur, such as chills, fatigue, fever, nausea, and joint\\nache, interrupt or slow the infusion...","Control group received non-activated autologous peripheral blood mononuclear cells.\\nNausea\\n129 (21.5)\\n3 (0.5)\\n45 (14.9)\\n0 (0.0)\\nJoint ache\\n118 (19.6)\\n11 (1.8)\\n62 (20.5)\\n5 (1.7)\\nHeadache\\n109 (18.1)\\n4 (0.7)\\n20 (6.6)\\n0 (0.0)\\nCitrate toxicity\\n89 (14.8)\\n0 (0.0)\\n43 (14.2)\\n0 (0.0)\\nParesthesia\\n85 (14.1)\\n1 (0.2)\\n43 (14.2)\\n0 (0.0)\\nVomiting\\n80 (13.3)\\n2 (0.3)\\n23 (7.6)\\n0 (0.0)\\nAnemia\\n75 (12.5)\\n11 (1.8)\\n34 (11.2)\\n7 (2.3)\\nConstipation\\n74 (12.3)\\n1 (0.2)\\n40 (13.2)\\n3 (1.0)\\nPain\\n74 (12.3)\\n7 (1.2)\\n20 (6.6)\\n3 (1.0)\\n...","AFRIN NODRIP ALLERGY SINUS NIGHT- oxymetazoline hydrochloride spray \\n \\nBayer HealthCare LLC.\\n----------\\nAfrin NoDrip Allergy Sinus Night UI1612461\\nDrug Facts\\nActive ingredient \\nPurpose\\nOxymetazoline hydrochloride 0.05%\\u2026\\u2026.\\u2026....Nasal decongestant\\nUses\\n\\u25aa \\ntemporarily relieves nasal congestion due to:\\n\\u25aa \\ncommon cold \\n\\u25aahay fever\\n\\u25aa \\nupper respiratory allergies\\n\\u25aa \\nreduces swelling of nasal passages so you can breathe more freely\\n\\u25aa \\ntemporarily relieves sinus congestion and pressure\\nWarnings\\n\\u25aa \\nAsk a do...","PROVENGE. Any of these may be signs of heart or lung problems.\\nyou develop numbness or weakness on one side of the body, decreased vision in one\\neye or difficulty speaking. Any of these may be signs of a stroke.\\nyou develop symptoms of thrombosis which may include: pain and/or swelling of an\\narm or leg with warmth over the affected area, discoloration of an arm or leg,\\nunexplained shortness of breath, chest pain that worsens on deep breathing.\\nyou get a fever over 100\\u00baF, or redness or pain at th...","Table 2 Summary of Overall Survival (All Patients as Randomized)\\n Hazard ratio and p-value based on the Cox Model adjusted for PSA (ln) and LDH (ln) and stratified\\nby bisphosphonate use, number of bone metastases, and primary Gleason grade.\\n Hazard ratio based on the unadjusted Cox Model (not pre-specified).\\n p-value based on a log-rank test (not pre-specified).\\nAbbreviations: CI = confidence interval.\\nStudy 1\\nStudy 2\\nPROVENGE \\n(N=341)\\nControl \\n(N=171)\\nPROVENGE\\n(N=82)\\nControl \\n(N=45)\\nOverall Sur...","PROVENGE group who underwent at least 1 leukapheresis procedure in four\\nrandomized, controlled clinical trials. The control group (n = 303) received non-activated\\nautologous peripheral blood mononuclear cells. Patients received 3 infusions of\\nPROVENGE or control every other week over a period of 4 weeks.\\nAlmost all (98.3%) patients in the PROVENGE group and 96% in the control group\\nreported an adverse event. In 67.4% of patients in the PROVENGE group, these adverse\\nevents were mild or moderate i...","PROVENGE- sipuleucel-t injection \\n \\nDendreon Pharmaceuticals LLC\\n----------\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\nThese highlights do not include all the information needed to use PROVENGE \\n (sipuleucel-\\nT) safely and effectively. See full prescribing information for PROVENGE. \\nPROVENGE \\n (sipuleucel-T) \\nSuspension for Intravenous Infusion \\nInitial U.S. Approval: 2010\\nRECENT MAJOR CHANGES\\nDosage and Administration\\n     Administration ( \\n2.2\\n)\\n9/2014\\nWarnings and Precautions\\n     Acute Infusion R...","Bayer HealthCare LLC.\\nMarketing Information\\nMarketing\\nCategory\\nApplication Number or Monograph\\nCitation\\nMarketing Start\\nDate\\nMarketing End\\nDate\\nOTC Monograph Drug\\nM012\\n11/09/2020\\nLabeler - \\nBayer HealthCare LLC. \\n(112117283)\\n \\nRevised: 12/2024","NDC 30237-8900-6: One bag individually packed in a carton.\\nPROVENGE is shipped directly to the infusing provider in a cardboard shipping box with\\na special insulated polyurethane container inside. The insulated container and gel packs\\nwithin the container are designed to maintain the appropriate transportation and storage\\ntemperature of PROVENGE until infusion.\\nUpon receipt, open the outer cardboard shipping box to verify the product and\\npatient-specific labels located on the top of the insulate...","PROVENGE\\n(sipuleucel-T)\\nThis leaflet is designed to help you understand treatment with PROVENGE (pronounced\\nPROH-venj). The more you understand your treatment, the better you will be able to\\nparticipate in your care. This leaflet does not take the place of talking with your doctor or\\nhealthcare professional about your medical condition or your treatment. If you have any\\nquestions, speak with your doctor.\\nWhat is PROVENGE?\\nPROVENGE is a prescription medicine that is used to treat certain patients...","Provenge. The clinical significance and causal relationship are uncertain. Most patients\\nhad multiple risk factors for these events. \\nCardiovascular disorders\\n:  In controlled clinical\\ntrials, myocardial infarctions were observed in 0.8% of patients in the PROVENGE group\\ncompared with 0.3% of patients in the control group.  In the postmarketing setting,\\nmyocardial infarctions have been observed following infusion of Provenge. The clinical\\nsignificance and causal relationship are uncertain. Most ...","Dendreon Pharmaceuticals LLC\\nPharmaceuticals LLC\\n968590237\\n, label(30237-8900)\\n \\nRevised: 10/2024","Relief from Allergies\\nfor a More Restful Night\\nReduces\\nSwelling of\\nNasal\\nPassages\\n1/2 FL OZ (15mL)\\nAFRIN NODRIP ALLERGY SINUS NIGHT  \\noxymetazoline hydrochloride spray\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:11523-0034\\nRoute of Administration\\nNASAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nOXYMETAZOLINE HYDROCHLORIDE\\n (UNII: K89MJ0S5VY) \\n(OXYMETAZOLINE\\n- UNII:8VLN5B44ZY)\\nOXYMETAZOLINE\\nHYDROCHLORIDE\\n0.5 mg\\n in 1 mL\\nInactive Ingredien...","Product Information\\nProduct Type\\nCELLULAR THERAPY\\nItem Code (Source)\\nNDC:30237-8900\\nRoute of Administration\\nINTRAVENOUS\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nSIPULEUCEL-T\\n (UNII: 8Q622VDR18) \\n(SIPULEUCEL-T - UNII:8Q622VDR18)\\nSIPULEUCEL-T\\n50000000 \\nInactive Ingredients\\nIngredient Name\\nStrength\\nPOTASSIUM CHLORIDE\\n (UNII: 660YQ98I10)\\n \\nCALCIUM CHLORIDE\\n (UNII: M4I0D6VV5M)\\n \\nWATER\\n (UNII: 059QF0KO0R)\\n \\nSODIUM CHLORIDE\\n (UNII: 451W47IQ8X)\\n \\nSODIUM LACTATE\\n (UNII: ...","ache, nausea, and vomiting. The incidence of severe events was greater following the\\nsecond infusion (2.1% vs. 0.8% following the first infusion), and decreased to 1.3%\\nfollowing the third infusion. Some (1.2%) patients in the PROVENGE group were\\nhospitalized within 1 day of infusion for management of acute infusion reactions. No\\nGrade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.\\nIn controlled clinical trials, severe (Grade 3) acute infusion reactions were rep...","supervision): 2 or 3 sprays in each nostril not more often than\\nevery 10 to 12 hours. Do not exceed 2 doses in any 24-hour\\nperiod.\\n\\u25aa children under 6 years of age: ask a doctor\\nTo Use: Shake well before use. Hold white tabs, press grooved area of cap firmly and\\nturn counter clockwise. Before using the first time, prime metered pump by depressing\\npump firmly several times. To spray, hold bottle with thumb at base and nozzle between\\nfirst and second fingers. Without tilting head, insert nozzle int...","ADVERSE REACTIONS\\nThe most common adverse reactions (incidence \\u2265 15%) are chills, fatigue, fever, back pain, nausea, joint\\nache, and headache. ( \\n6\\n)\\nTo report SUSPECTED ADVERSE REACTIONS, contact Dendreon Pharmaceuticals LLC at 1-\\n877-336-3736 or FDA at 1-800-FDA-1088 or \\nwww.fda.gov/medwatch\\n.\\nSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.\\nRevised: 7/2017\\nFULL PRESCRIBING INFORMATION: CONTENTS\\n*\\n1 INDICATIONS AND USAGE\\n2 DOSAGE AND ADMINISTRATION\\n2.1 Dose\\n2.2 Admi..."]],["color",["#ba0e0e","#0a980a","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#0a980a","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#0a980a","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e"]]]}}},"view":{"type":"object","name":"CDSView","id":"p2333","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p2334"}}},"glyph":{"type":"object","name":"Scatter","id":"p2329","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.7},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p2330","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p2331","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p2347","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p2338","attributes":{"selected":{"type":"object","name":"Selection","id":"p2339","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p2340"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"tv2WwbQgjMFX+ZzBviuQwdO3ksFPNpTBnMONwVseiMEIq5nBvvCgwdt2msH47p/BeoOUwRDco8Fl1p7BNfiawXwlmMHV9JLBAnGNwfyfgsGip4HBpI58wbdTeMGI9ojB"},"shape":[24],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"7BGaQIJpkkCK9pVAGqetQFux3UDm38FAA8rOQI+nu0As5bJAslawQCP70kD0CM1ARPCEQDyrkkAVgXVAJ904QK8JZkBcyz5AuFVDQFDBn0BC/IlAaD9rQJpmlUA9F2tA"},"shape":[24],"dtype":"float32","order":"little"}]]}}},"view":{"type":"object","name":"CDSView","id":"p2348","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p2349"}}},"glyph":{"type":"object","name":"Scatter","id":"p2344","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.2}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p2345","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.1},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p2346","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.2}}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p2301","attributes":{"logo":"grey","tools":[{"type":"object","name":"PanTool","id":"p2316"},{"type":"object","name":"WheelZoomTool","id":"p2317","attributes":{"renderers":"auto"}},{"type":"object","name":"BoxZoomTool","id":"p2318","attributes":{"overlay":{"type":"object","name":"BoxAnnotation","id":"p2319","attributes":{"syncable":false,"level":"overlay","visible":false,"left":{"type":"number","value":"nan"},"right":{"type":"number","value":"nan"},"top":{"type":"number","value":"nan"},"bottom":{"type":"number","value":"nan"},"left_units":"canvas","right_units":"canvas","top_units":"canvas","bottom_units":"canvas","line_color":"black","line_alpha":1.0,"line_width":2,"line_dash":[4,4],"fill_color":"lightgrey","fill_alpha":0.5}}}},{"type":"object","name":"ResetTool","id":"p2324"},{"type":"object","name":"SaveTool","id":"p2325"},{"type":"object","name":"HoverTool","id":"p2292","attributes":{"renderers":[{"id":"p2332"}],"tooltips":"\\n    &lt;div style=\\"width:400px;\\"&gt;\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\n    &lt;/div&gt;\\n    "}}]}},"left":[{"type":"object","name":"LinearAxis","id":"p2311","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p2312","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p2313"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p2314"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p2306","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p2307","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p2308"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p2309"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p2310","attributes":{"axis":{"id":"p2306"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p2315","attributes":{"dimension":1,"axis":{"id":"p2311"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Legend","id":"p2335","attributes":{"title":"Question Correctness","title_text_color":"#B1B1B1","title_text_font_style":"bold","border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p2336","attributes":{"label":{"type":"value","value":"False"},"renderers":[{"id":"p2332"}],"index":0}},{"type":"object","name":"LegendItem","id":"p2337","attributes":{"label":{"type":"value","value":"True"},"renderers":[{"id":"p2332"}],"index":1}}]}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}}}],"tabs_location":"below"}}]}}';
        const render_items = [{"docid":"7e4e7d98-6689-46c2-afad-27dcd094f80f","roots":{"p2351":"d5baf671-b7cb-42c1-bb6c-95164dc94d80"},"root_ids":["p2351"]}];
        root.Bokeh.embed.embed_items(docs_json, render_items);
        }
        if (root.Bokeh !== undefined) {
          embed_document(root);
        } else {
          let attempts = 0;
          const timer = setInterval(function(root) {
            if (root.Bokeh !== undefined) {
              clearInterval(timer);
              embed_document(root);
            } else {
              attempts++;
              if (attempts > 100) {
                clearInterval(timer);
                console.log("Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing");
              }
            }
          }, 10, root)
        }
      })(window);
    });
  };
  if (document.readyState != "loading") fn();
  else document.addEventListener("DOMContentLoaded", fn);
})();
    </script>

                <div id="d5baf671-b7cb-42c1-bb6c-95164dc94d80" data-root-id="p2351" style="display: contents;"></div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">

                <div class="section-title">SELECTED METRICS</div>

                

            </div>
        </div>

        
    </div>
</div>



<script type="text/javascript">
    function opentab(evt, name) {
    // Declare all variables
    let i, tabcontent, tablinks;

    // Get all elements with class="tabcontent" and hide them
    tabcontent = document.getElementsByClassName("tabcontent");
    for (i = 0; i < tabcontent.length; i++) {
        tabcontent[i].style.display = "none";
    }

    // Get all elements with class="tablinks" and remove the class "active"
    tablinks = document.getElementsByClassName("tablinks");
    for (i = 0; i < tablinks.length; i++) {
        tablinks[i].className = tablinks[i].className.replace(" active", "");
    }

    // Show the current tab, and add an "active" class to the button that opened the tab
    document.getElementById(name).style.display = "block";
    evt.currentTarget.className += " active";
}
</script>
